|
|
|
|
|
|
|
|
Full Text (technical)
Published: 17 May 2016
....Human
epididymis protein-4 (HE4/WFDC2) is a small secretory protein that
belongs to the family of whey acidic protein (WAP) domain-containing
anti-proteases [3], and has been shown to possess cross-class anti-protease activity itself [4].
It is overexpressed in ovarian cancer tissues compared to normal
ovaries, and has been identified as a novel biomarker for EOC [5, 6].
Serum levels predict ovarian cancer with equivalent sensitivity to
CA125, but with the advantage that HE4 is less frequently elevated in
patients with benign gynecological conditions [5]. A multicenter study led by our institution established a new algorithm for the diagnosis of women with an ovarian mass [6].
The FDA-approved Risk of Ovarian Malignancy Algorithm (ROMA) uses HE4
along with CA125 and menopausal status to predict a woman’s risk of
ovarian cancer and monitor disease with improved sensitivity and
specificity over the Risk of Malignancy Index (RMI) that used CA125,
pelvic sonography, and menopausal status [6].
Recently, HE4 has been associated with the development of chemoresistance clinically.....Discussion
The
ways in which HE4 affects chemoresistance are likely multi-factorial
and cell type-specific. In cells that already display a high degree of
chemoresistance due to other mechanisms, such as OVCAR8 cells, the
effect of increasing levels of HE4 may be minimal. In contrast, in cells
with low levels of HE4 that are not as chemoresistant, increasing the
level of HE4 may produce dramatic changes in apoptotic response to drug
treatment, as we have observed in SKOV3 cells....
(abstract) Conclusion:
Overexpression of HE4 promotes
collateral resistance to cisplatin and paclitaxel, and downregulation
of HE4 partially reverses this chemoresistance. Multiple factors could
be involved in HE4-mediated chemoresistance, including deregulation of
MAPK signaling, as well as alterations in tubulin levels or stability.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.